CPRX

Catalyst Pharmaceuticals Stock Analysis

AI Rating

Good
  • Quality9/10
  • Growth↑ 7/10
  • Momentum↑ 5/10
Catalyst Pharmaceuticals sales and earnings growth
CPRX Growth
Good
  • Revenue Y/Y↑ 25.56%
  • EPS Y/Y↑ 43.20%
  • FCF Y/Y↓ 4.70%
Catalyst Pharmaceuticals gross and profit margin trends
CPRX Profitability
Great
  • Gross margin ↑ 85.70%
  • EPS margin↑ 37.60%
  • ROIC↑ 370.30%
Catalyst Pharmaceuticals net debt vs free cash flow
CPRX Risk
Great
  • Debt / Equity↓ 0.0
  • Debt / FCF↓ 0.0
  • Interest coverage↓ NA

Catalyst Pharmaceuticals stock is less volatile than the overall market, so it's low risk. We give it a Great risk rating.

More Biotechnology stocks ↗